Not a single study
Story checked
Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases (opens in a new tab)
news-medical.net · 2026-09-24
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases
news-medical.net · 2026-09-24
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Also referencedpresented as the new finding
Therapeutic oligonucleotides as genetic medicines: The current state and future perspective
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedThe article says a recent review in Cell Reports Medicine examined the mechanisms, chemical modifications, delivery strategies, clinical development, and future applications of therapeutic oligonucleotides as genetic medicines.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedThe article says chemical modifications and delivery advances have improved oligonucleotide stability, efficacy, durability, and target specificity, but delivery beyond the liver, safety, and individualized design remain major challenges.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedThe article says 21 therapeutic oligonucleotides had received regulatory approval, with two later withdrawn, and that these therapies include treatments for several rare and common disorders.View evidenceHide evidence
As stated21 approved, 2 withdrawn
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedThe article says inclisiran, a GalNAc-conjugated siRNA targeting PCSK9, produced approximately 50% reductions in LDL cholesterol in phase 3 trials, with effects sustained for at least 18 months.View evidenceHide evidence
As statedapproximately 50% reductions; sustained for at least 18 months
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe article says the field is expanding beyond rare diseases, with inclisiran established in common hypercholesterolemia and additional ASOs and siRNAs targeting PCSK9, ANGPTL3, APOC3, and lipoprotein(a) in development.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Evolution of siRNA Therapeutics: From Mechanistic Foundations to Clinical Expansion.
Pharmaceutics · 2026 · PubMed, Europe PMC
INCLISIRAN THERAPY FOR LDL-CHOLESTEROL REDUCTION: CLINICAL OUTCOMES AND SAFETY PROFILE
Atherosclerosis · 2026 · Crossref
RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside.
Research (Washington, D.C.) · 2026 · PubMed
LDL cholesterol and familial hypercholesterolemia in children. Significance of familial history in detecting familial hypercholesterolemia
Atherosclerosis · 2017 · Crossref
RNA-Based Therapies for Hypercholesterolemia and Coronary Artery Disease.
Cureus · 2026 · PubMed
And 10 more candidates considered.